Advanced Search


Study ID Status Title Patient Level Data
115696 Completed An Adaptive, Two part, Two period, Single Sequence, Drug Interaction Study between Dolutegravir 50 mg and Prednisone in Adult Healthy Volunteers
115697 Completed A Phase I, open label, randomized, two cohort, two period, oneway study to evaluate the effect of Boceprevir and Telaprevir onDolutegravir pharmacokinetics in healthy adult subjects (ING115697)
115698 Completed A Phase 1, Open-Label, 2-Period Drug Interaction Study to Assess Steady State Plasma Methadone Enantiomer Pharmacokinetics Following Co-Administration of Methadone QD with Dolutegravir (GSK1349572) 50 mg twice daily in Opiate-Dependent, HIV Seronegative Adult Subjects.
115705 Completed A single blind, placebo controlled, parallel group, single ascending intravenous dose study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of SB-240563 (mepolizumab) in healthy Japanese male subjects. Study Listed on
115707 Completed An Open-label, Randomized, Single Dose, Four-Period Crossover study to compare the Bioavailability of Fixed Dose Combination Capsule Formulations of Dutasteride and Tamsulosin Hydrochloride (0.5 mg/0.2 mg) with 10% and 15% of enteric coated pellets with Harnal-D tablets and Harnal capsules co-administered with dutasteride (0.5 mg) Soft Gel Capsules in Healthy Male Subjects of North East Asian ancestry Study Listed on
115708 Completed An Open-label, Randomized, Single Dose, Multi-stage, Cross-over study to determine the Relative bioavailability of Fixed Dose Combination Products containing a 3-oblong dutasteride soft gel capsule and tamsulosin (0.5 mg dutasteride /0.2 mg tamsulosin HCl) pellets having a range of tamsulosin release rates produced by different mixtures of enteric coated and uncoated pellets relative to Harnal-D Tablets, in Healthy Male Subjects of North East Asian ancestry. Study Listed on
115711 Completed Phase 1, Open Label Study to Evaluate the Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
115717 Completed A Phase I/IIa, First Time in Human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency Study Listed on
115719 Completed A Randomised, Placebo Controlled, Ascending, Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278 Study Listed on
115720 Completed A Double-Blind, 3-Part Crossover Study to Assess the Pharmacokinetics and Tolerability of Single Doses of Gabapentin Enacarbil and Morphine Administered Alone and in Combination in Healthy Subjects
115730 Completed PGx423 Pharmacogenetic evaluation of efficacy of lapatinib in EGF104900, EGF20009, EGF105084 and VEG20007
115739 Completed Safety and reactogenicity of GSK Biologicals’ dTpa vaccine (Boostrix™) in healthy Vietnamese children Study Listed on
115774 Completed An Open-Label, Non-Randomized, Two-Period, Cross-Over, Mass Balance Study to Investigate the Recovery, Excretion and Pharmacokinetics of 14C-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects (BTZ115774) Study Listed on
115775 Completed A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, 4-Period Crossover Study to Evaluate the Effect of GSK2140944 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers Study Listed on
115777 Completed Cardiovascular Events in Cancer Patients Receiving Highly Emetogenic or Moderately Emetogenic Chemotherapy
115802 Terminated A single-centre, masked, placebo-controlled four part study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and repeat doses of the CC-chemokine receptor 3 (CCR3) antagonist, GW824575, coadministered with or without food in healthy male subjects Study Listed on
115805 Completed A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily via a Novel Dry Powder Inhaler Compared with Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily via the HandiHaler in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease Study Listed on
115806 Completed A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects
115811 Terminated A Randomised, Multicentre, Double-Blind, Placebo-Controlled Study Of Ambrisentan In Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
115812 Completed An open label Phase IIIb study to evaluate efficacy and safety of Ambrisentan in Chinese patients with pulmonary arterial hypertension (PAH)
115813 Completed Identification and characterization of bacteria in the lower airways of children aged ≥ 6 months to < 6 years with suspected lower respiratory tract infections (LRTI) in Spain.
115816 Completed A randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease exhibiting delayed gastric emptying
115829 Relinquished An Open-Label, Two Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination with the AKT Inhibitor GSK2110183 in Subjects with Solid Tumors and Multiple Myeloma
115830 Completed A Double blind, Placebo controlled, Phase I Dose-ranging Study to Evaluate the Activity of SRT2379 on Endotoxin induced Inflammatory Response in Healthy Male Subjects Study Listed on
115831 Completed Effects of Brain Derived Neurotrophic Factor (BDNF) gene Polymorphism on Brain Imaging and Behavioural Biomarkers of Plasticity



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.